Indeed, many patients with ROS-1- MET-, RET-, NTRK-, BRAF-, or HER-2-mutated NSCLC currently receive ICIs as a first-line therapy due to the lack of genomic information, although this is reducing due to the broader use of NGS and liquid biopsy techniques. Here, BRAF is linked to non-small cell lung carcinoma.